A PERSONALISED APPROACH TO IVF
![slider left background image](https://hcp.ferring.co.uk/wp-content/uploads/2022/09/Artboard-2Rekovelle-min.png)
![slider left background image](https://hcp.ferring.co.uk/wp-content/uploads/2022/09/Flowers-Rekovelle-2-15jun2023.png)
![slider right background image](https://hcp.ferring.co.uk/wp-content/uploads/2022/09/Rekovelle-video-grabs-7-min.jpeg)
![slider right background image](https://hcp.ferring.co.uk/wp-content/uploads/2022/09/Rekovelle-video-grabs-7-min.jpeg)
Adverse Event reporting information can be found in footer
Request a Meeting
Delivering personalised medicine through individualised dosing.
The first human recombinant FSH:
A distinct glycosylation pattern compared with follitropin alpha leading to:
Individually dosed using the patient’s body weight and the ELECSYS® anti-Müllerian hormone (AMH) Plus immunoassay from Roche, ACCESS® AMH Advanced from Beckman Coulter or LUMIPULSE G® AMH from Fujirebio as a companion diagnostic1,2,4
Job Code: UK-REK-2300009 - Date of preparation: July 2023